Get notified when JUNS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditors issued going-concern opinions for both 2024 and 2025, indicating substantial doubt about the company's ability to continue as a going concern.
Jupiter Neurosciences prices $2M primary offering at $0.28/share; net proceeds $1.7M
Filed May 21, 2026 · ~1 min read
Key Changes
-
high
Company offering 7,142,858 shares at $0.28 each; gross proceeds $2M, net proceeds $1.7M after fees.
The Offering verify on EDGAR → -
medium
Net proceeds to be used for working capital and general corporate purposes, with broad management discretion.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $0.31 per share; net tangible book value is negative.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade JUNS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify